Keywords: Psoriasis, Market, Biologics, Interleukin, TNF-alpha inhibitors, Enbrel, Humira, Stelara

Psoriasis drug market expected to double to $6.8 Billion in 2019, driven by biologics penetration and Interleukin/TNF-alpha inhibitors

Article | 10 August 2010

Print This

The continued uptake of marketed and emerging interleukin and TNF-alpha inhibitors, along with a twofold increase in the penetration of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in